| Literature DB >> 33192575 |
Lijin Guo1,2,3, Weiling Huang1,2,3, Feng Tong1,3, Xiaolan Chen1,2,3, Sen Cao1,2,3, Haiping Xu1,2,3, Wei Luo1,2,3, Zhenhui Li1,2,3, Qinghua Nie1,2,3.
Abstract
Coccidiosis is a major hazard to the chicken industry, but the host's immune response to coccidiosis remains unclear. Here, we performed Eimeria coccidia challenge in 28-day-old ROSS 308 broilers and selected the bursa from the three most severely affected individuals and three healthy individuals for RNA sequencing. We obtained 347 DEGs from RNA-seq and found that 7 upregulated DEGs were enriched in Cytokine-cytokine receptor interaction pathway. As the DEGs with the highest expression abundance in these 7 genes, TNFRSF6B was speculated to participate in the process of host's immune response to coccidiosis. It is showed that TNFRSF6B can polarize macrophages to M1 subtype and promote inflammatory cytokines expression. In addition, the expression of TNFRSF6B suppressed HD11 cells apoptosis by downregulating Fas signal pathway. Besides, TNFRSF6B-mediated macrophages immunity activation can be reversed by apoptosis. Overall, our study indicates that TNFRSF6B upregulated in BAE, is capable of aggravating the inflammatory response by inhibiting macrophages apoptosis via downregulating Fas signal pathway, which may participate in host's immune response to coccidiosis.Entities:
Keywords: Fas signal pathway; RNA-seq; TNFRSF6B; coccidiosis; inflammatory response; macrophages apoptosis; macrophages polarization
Year: 2020 PMID: 33192575 PMCID: PMC7662072 DOI: 10.3389/fphys.2020.573676
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Blast Analysis of Transcriptome from RNA-seq. (A) The quantity statistics of DEGs, in which the red column representing upregulated DEGs and the green representing downregulated DEGs. (B) Heatmap of 347 differentially expressed genes (DEGs) between BAE and BAN, in which rows representing genes and columns representing different groups.
FIGURE 2qPCR Validation for DEGs from RNA-seq. 12 DEGs were randomly selected for qPCR validation. The data was shown as mean ± SEM; *P < 0.05, **P < 0.01, ns: no significant difference.
FIGURE 3GO and KEGG Analysis for DEGs. (A) The top GO terms for DEGs, in which rows representing GO terms and columns representing the value of “–log10(KS)”. (B) The top 20 enriched pathways in KEGG pathway analysis for DEGs, in which rows representing pathways and columns representing the percentage (%) of rich factor.
The top 20 enriched KEGG pathways.
| Arginine biosynthesis | 8.59 | 0.42 | |
| Small cell lung cancer | 60.11 | 1.00 | |
| Alanine, aspartate and glutamate metabolism | 5.01 | 1.00 | |
| Cytokine-cytokine receptor interaction | 2.36 | 1.00 | |
| Nicotinate and nicotinamide metabolism | 3.76 | 1.00 | |
| Transcriptional misregulation in cancer | 8.59 | 1.00 | |
| SNARE interactions in vesicular transport | 3.44 | 1.00 | |
| Cardiac muscle contraction | 2.50 | 1.00 | |
| Other types of O-glycan biosynthesis | 3.34 | 1.00 | |
| Biosynthesis of amino acids | 2.40 | 1.00 | |
| Adherens junction | 2.23 | 1.00 | |
| Intestinal immune network for IgA production | 2.80 | 1.00 | |
| Pathways in cancer | 5.46 | 1.00 | |
| Taurine and hypotaurine metabolism | 5.46 | 1.00 | |
| Ascorbate and aldarate metabolism | 5.46 | 1.00 | |
| Glutathione metabolism | 2.50 | 1.00 | |
| Glycosphingolipid biosynthesis – ganglio series | 4.62 | 1.00 | |
| Cell adhesion molecules (CAMs) | 1.73 | 1.00 | |
| Amino sugar and nucleotide sugar metabolism | 2.31 | 1.00 | |
| Notch signaling pathway | 2.27 | 1.00 |
DEGs enriched in Cytokine-cytokine receptor interaction pathway.
| TNF receptor superfamily member 6b | 14.22 | 5.13 | 0.00 | 1.41 | Up | |
| Anti-mullerian hormone receptor type 2 | 5.52 | 1.90 | 0.02 | 1.29 | Up | |
| Interleukin 10 | 4.87 | 0.29 | 0.00 | 3.76 | Up | |
| Tumor necrosis factor superfamily member 13b | 3.85 | 1.44 | 0.00 | 1.40 | Up | |
| TNF receptor superfamily member 25 | 3.20 | 1.66 | 0.03 | 0.98 | Up | |
| Interleukin 1 receptor type 1 | 0.97 | 0.37 | 0.03 | 1.37 | Up | |
| Interleukin 12 receptor subunit beta 2 | 0.89 | 0.56 | 0.00 | 1.43 | Up |
FIGURE 4TNFRSF6B polarizes macrophages to M1 subtype. (A) The mRNA expression of M1 macrophages polarization marker genes was upregulated or downregulated after the overexpression or knockdown of TNFRSF6B by qPCR. (B) The secretion of IL-1, IL-2, IL-6, and IFNγ from HD11 cells after the transfection with pcDNA3.1-TNFRSF6B and si-TNFRSF6B by ELISA analysis. (C) The mRNA expression of macrophages activation-related genes was upregulated or downregulated after the overexpression or knockdown of TNFRSF6B by qPCR. (D) The secretion of TLR4, M-CSF, and MCP-1 in cell supernatant after the transfection with pcDNA3.1-TNFRSF6B and si-TNFRSF6B by ELISA analysis. (E) ROS level analysis in HD11 cells with the overexpression of TNFRSF6B. (F) ROS level analysis in HD11 cells with the knockdown of TNFRSF6B. (G) NO level detection after the overexpression or knockdown of TNFRSF6B. The data was shown as mean ± SEM; *P < 0.05, **P < 0.01, ns, no significant difference.
FIGURE 5The Apoptosis reversed the TNFRSF6B-mediated strengthening effect on the immune response of macrophages. (A) The mRNA expression of IL-1β and IL-6 after the treatment of TNFRSF6B overexpression and PKC inhibitor. (B) The mRNA expression of IL-1β and IL-6 after the treatment of TNFRSF6B knockdown and PKC inhibitor. (C) The secretion levels of IL-1, IFN-γ, and IL-2 after the treatment of TNFRSF6B overexpression and PKC inhibitor. (D) The mRNA expression of macrophages activation-related genes after the treatment of TNFRSF6B overexpression and PKC inhibitor. (E) The mRNA expression of macrophages activation-related genes after the treatment of TNFRSF6B knockdown and PKC inhibitor. (F) The secretion levels of TLR4 and M-CSF after the treatment of TNFRSF6B overexpression and PKC inhibitor. (G) The mRNA expression of IL-2 and IL-12 after the treatment of TNFRSF6B overexpression and PKC inhibitor. (H) The mRNA expression of IL-2 and IL-12 after the treatment of TNFRSF6B knockdown and PKC inhibitor. (I) The mRNA expression of NOS2 after the treatment of TNFRSF6B overexpression and PKC inhibitor. (J) The mRNA expression of NOS2 after the treatment of TNFRSF6B knockdown and PKC inhibitor. (K) Model of TNFRSF6B-mediated macrophages immune activation. The data was shown as mean ± SEM; *P < 0.05, **P < 0.01, ns, no significant difference.